Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total neoadjuvant SOX plus sintilimab versus perioperative SOX in locally advanced gastric cancer
ChiCTR2400082139Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab, oxaliplatin and tegafur in gastric cancer (GC) and gastric adenocarcinoma (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: TRG 0/1 rate. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
sintilimaboxaliplatintegafur
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400082139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082139.